Equities

Carasent ASA

Carasent ASA

Actions
  • Price (NOK)19.50
  • Today's Change0.00 / 0.00%
  • Shares traded11.93k
  • 1 Year change+42.96%
  • Beta--
Data delayed at least 20 minutes, as of Nov 07 2024 10:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carasent ASA is a Norway-based technology Company. The strategy of Carasent is to develop and expand digitalization that helps customers to meet challenges in providing efficient and qualitative health care services. The Company provides its customers with cloud based medical record software solutions and a broad ecosystem of integrated services, in a range of healthcare segments. Carasent focuses on businesses that develop entrepreneurial and e-health solutions. Operating business activities in the Group can be categorized into six different categories; Software as a Service (SaaS), Add-on services, Consulting, License, maintenance and other. All services are delivered to the health care sector.

  • Revenue in NOK (TTM)264.80m
  • Net income in NOK-7.94m
  • Incorporated2001
  • Employees169.00
  • Location
    Carasent ASAc/o Advokatsenteret ASKristian August gate 14BILLINGSTAD 0164NorwayNOR
  • Phone+1 7 038902800
  • Fax+1 7 038902801
  • Websitehttps://carasent.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.